Dren Bio
4 known investors
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical Devices
Investors · 4
In the news
- Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platformbusinesswire.com · 2022
- Dren Bio, Inc. Licenses ATX-Gx™ Transgenic Mice Platformalloytx.com · 2022
- Dren Bio - 2025 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Dren Bio - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Dren Bio Raises $60 Million to Develop Therapies for Rare Cancers - Global Genesglobalgenes.org · 2020
- Dren Bio Raises $60M in Series A Financing - FinSMEsfinsmes.com · 2020